Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published February 18, 2021 | Published + Supplemental Material
Journal Article Open

Limited effects of long-term daily cranberry consumption on the gut microbiome in a placebo-controlled study of women with recurrent urinary tract infections

Abstract

Background: Urinary tract infections (UTIs) affect 15 million women each year in the United States, with > 20% experiencing frequent recurrent UTIs. A recent placebo-controlled clinical trial found a 39% reduction in UTI symptoms among recurrent UTI sufferers who consumed a daily cranberry beverage for 24 weeks. Using metagenomic sequencing of stool from a subset of these trial participants, we assessed the impact of cranberry consumption on the gut microbiota, a reservoir for UTI-causing pathogens such as Escherichia coli, which causes > 80% of UTIs. Results: The overall taxonomic composition, community diversity, carriage of functional pathways and gene families, and relative abundances of the vast majority of observed bacterial taxa, including E. coli, were not changed significantly by cranberry consumption. However, one unnamed Flavonifractor species (OTU41), which represented ≤1% of the overall metagenome, was significantly less abundant in cranberry consumers compared to placebo at trial completion. Given Flavonifractor's association with negative human health effects, we sought to determine OTU41 characteristic genes that may explain its differential abundance and/or relationship to key host functions. Using comparative genomic and metagenomic techniques, we identified genes in OTU41 related to transport and metabolism of various compounds, including tryptophan and cobalamin, which have been shown to play roles in host-microbe interactions. Conclusion: While our results indicated that cranberry juice consumption had little impact on global measures of the microbiome, we found one unnamed Flavonifractor species differed significantly between study arms. This suggests further studies are needed to assess the role of cranberry consumption and Flavonifractor in health and wellbeing in the context of recurrent UTI. Trial registration: Clinical trial registration number: ClinicalTrials.govNCT01776021.

Additional Information

© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Received 16 September 2020; Accepted 28 January 2021; Published 18 February 2021. We would like to thank Colin Worby, Rauf Salamzade, and Andrew Kau, as well as other members of the Earl and Hultgren labs, for helpful discussions, and Whitney Howe for additional project management. We would also like to thank Anthony Fodor for critical reading of the manuscript. This project has been funded in part by Ocean Spray (Lakeville-Middleboro, MA), with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No.:HHSN272200900018C and Grant Number U19AI110818 to the Broad Institute, with federal funds from the National Institute of Allergy and Infectious Disease, National Institutes of Health, Department of Health and Human Services, under Grant Number U01AI095542 to Washington University in St. Louis, and with federal funds from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, under Grant Number R01DK121822 to Washington University in St. Louis. Availability of data and materials: The 16S rRNA and WMS sequencing reads generated and analyzed during the current study are available in the NCBI SRA repository, under the BioProject PRJNA528960 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA528960). Additional data generated and analyzed during this study are included in this published article and its additional files. Timothy J. Straub and Wen-Chi Chou contributed equally to this work. Author Contributions: HLS, KWD, SJH, CK, and AME conceived of and designed the study. WC, SBC, KLK, OJK, ET, and MAJH processed samples and coordinated delivery to the Broad for sequencing. TJS, WC, ALM, HLS, BJW, and CAD processed and participated in analysis of sequencing data. KWD, SJH and AME provided project oversight. TJS, WC, ALM, HLS, and AME drafted the manuscript. All authors read and approved the final manuscript. Ethics approval and consent to participate: The clinical trial was approved by the institutional review boards at the Quorum Review IRB (Seattle, Washington) and the National Security Agency for Medicines and Health Products and an Ethical Research Committee (Committee for Personal Protection) (Saint-Denis, France). This study was reviewed and approved by MIT's Committee on the Use of Humans as Experimental Subjects (Cambridge, Massachusetts), under protocol #1504007050. Informed consent was obtained for all participants. Consent for publication: Not applicable. Competing interests: KLK and CK are employees of Ocean Spray (Lakeville-Middleboro, MA). All other authors have no competing interests to declare.

Attached Files

Published - s12866-021-02106-4.pdf

Supplemental Material - 12866_2021_2106_MOESM10_ESM.pdf

Supplemental Material - 12866_2021_2106_MOESM11_ESM.pdf

Supplemental Material - 12866_2021_2106_MOESM12_ESM.pdf

Supplemental Material - 12866_2021_2106_MOESM13_ESM.pdf

Supplemental Material - 12866_2021_2106_MOESM14_ESM.pdf

Supplemental Material - 12866_2021_2106_MOESM15_ESM.pdf

Supplemental Material - 12866_2021_2106_MOESM16_ESM.pdf

Supplemental Material - 12866_2021_2106_MOESM17_ESM.docx

Supplemental Material - 12866_2021_2106_MOESM1_ESM.txt

Supplemental Material - 12866_2021_2106_MOESM2_ESM.xlsx

Supplemental Material - 12866_2021_2106_MOESM3_ESM.xlsx

Supplemental Material - 12866_2021_2106_MOESM4_ESM.txt

Supplemental Material - 12866_2021_2106_MOESM5_ESM.txt

Supplemental Material - 12866_2021_2106_MOESM6_ESM.txt

Supplemental Material - 12866_2021_2106_MOESM7_ESM.txt

Supplemental Material - 12866_2021_2106_MOESM8_ESM.pdf

Supplemental Material - 12866_2021_2106_MOESM9_ESM.pdf

Files

12866_2021_2106_MOESM10_ESM.pdf
Files (9.0 MB)
Name Size Download all
md5:fc613746184bb5bdaf58b5313553e749
330.0 kB Preview Download
md5:77e6992c957b40903dfced0bb5985f3e
456.4 kB Preview Download
md5:0800a1e2c8cfd56fa52726372cdce094
1.5 MB Download
md5:06bb7b243deabd89eddb0bdbd7983982
294.7 kB Preview Download
md5:13694ae532f8cd7e1e3a54272c43e1ea
582.8 kB Preview Download
md5:22ca2ddedd7aa420e97ab5e158961322
1.4 MB Preview Download
md5:f00bd2932354be65252427580f2b104d
208.3 kB Preview Download
md5:e923f1294a5c519600df12357710faf6
317.3 kB Preview Download
md5:398da31bc3d34ef841552dfe2753c530
216.7 kB Preview Download
md5:6b823fc9dd1c592aa3696fc2d7259b80
445.2 kB Preview Download
md5:f91bb5fc351292bd05a4cc2271eda0ea
655.3 kB Preview Download
md5:42f761a985481e2e66299364d215413b
68.5 kB Preview Download
md5:07f74bd06098f3fc97e7e27ffb9112d0
644.2 kB Preview Download
md5:9f7a83128e596a72c5c928a50200d5f4
990.1 kB Preview Download
md5:2ceced3268678504c1b522f639399092
4.7 kB Preview Download
md5:2c6e7440dccfbc2a33bc50ed58ad7e11
160.9 kB Preview Download
md5:30d0594efdd6d10f8c51fd3eea414454
17.0 kB Download
md5:4cc4def7ff6710a95cad8deef99a11b8
658.1 kB Download

Additional details

Created:
September 15, 2023
Modified:
October 23, 2023